| Grant number: | 19/14526-0 |
| Support Opportunities: | Research Grants - Young Investigators Grants |
| Start date: | February 01, 2020 |
| End date: | January 31, 2026 |
| Field of knowledge: | Biological Sciences - Immunology - Applied Immunology |
| Principal Investigator: | Gustavo Cabral de Miranda |
| Grantee: | Gustavo Cabral de Miranda |
| Host Institution: | Faculdade de Medicina (FM). Universidade de São Paulo (USP). São Paulo , SP, Brazil |
| Associated researchers: | Jorge Elias Kalil Filho |
| Associated research grant(s): | 20/05146-7 - Development of vaccine anti-SARS-CoV-2 based on VLPs, AP.R |
| Associated scholarship(s): | 24/13269-2 - Characterization and humanization of anti-Chikungunya and Zika Virus monoclonal antibodies,
BP.TT 24/00509-5 - Communication as a tool to integrate vaccination and immunotherapies to the society, BP.JC 24/00510-3 - Communication as a tool to integrate vaccination and immunotherapies to the society, BP.JC + associated scholarships - associated scholarships |
Abstract
Neglected tropical diseases typically affect low- to middle income patients; drug and vaccine development by vaccine industries is impaired due to the lack of prospects for financial gain. Streptococcus pyogenes, also termed Group A Streptococcus (GAS), is a human restricted pathogen responsible for a large variety of diseases, such as Acute Rheumatic Fever (ARF) and Rheumatic Heart Disease (RHD), which are estimated to induce more than a half million deaths due to serious GAS worldwide and has caused severe problems in Brazil. RHD is one of the major causes of heart valve replacement surgery in Brazil and several countries. Chikungunya Virus (CHIKV) is an emerging infectious disease that has become a worldwide threat and notified in over than 60 countries. A Severe Chronic Arthritis develops in a significant proportion of infected patients. According to WHO, more than one million cases are reported annually only in the Americas, where most of the cases in Brazil. Therefore, the development of safe and effective vaccines against S. pyogenes and CHIKV will prevent an extensive human morbidity and mortality caused by these pathogens. In this project we propose the development of vaccines against S. pyogenes and CHIKV based on Virus Like Particles (VLPs), such as Bacteriophage Qbeta (Qß) as well as murine polyomavirus VP1 VLPs. The proposal of VLPs construction and characterisation such as new platform to be used for the study of vaccines will be key for vaccine studies at the Heart Institute, University of São Paulo, as well as to Brazil in general; as it will be the important step to stablish strategies to use VLPs to display and deliver heterologous antigens. Besides that, will be expanded and strengthen collaborations with international recognised universities, such as University of Oxford, United Kingdom and the University Hospital of Bern, Switzerland. (AU)
| Articles published in Agência FAPESP Newsletter about the research grant: |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |